Trisopt Ophthalmic Suspension 5ml

Trisopt Ophthalmic Suspension 5ml interacts with the following medicines:

• ​​Oral Carbonic Anhydrase Inhibitors: Medicines such as acetazolamide may interact with Trisopt Ophthalmic Suspension 5ml, potentially increasing the risk of systemic carbonic anhydrase inhibition and acid–base or electrolyte disturbances.
• High-dose Salicylate Therapy: Large doses of salicylates may interact with the carbonic anhydrase inhibitor component of Trisopt Ophthalmic Suspension 5ml, increasing the risk of metabolic acidosis and salicylate toxicity.
• CNS Depressants: Medicines such as diazepam or alprazolam may enhance the central nervous system effects of the brimonidine component in Trisopt Ophthalmic Suspension 5ml, possibly leading to increased drowsiness or sedation.
• Antihypertensives/Cardiac Glycosides: Concomitant use with antihypertensives or cardiac glycosides such as digoxin may potentiate hypotension or bradycardia due to additive cardiovascular effects.
• Tricyclic Antidepressants: Medicines such as amitriptyline may interfere with the intraocular pressure-lowering effect of brimonidine in Trisopt Ophthalmic Suspension 5ml, potentially reducing its efficacy.
• Monoamine Oxidase Inhibitors: MAO inhibitors may increase systemic effects of brimonidine in Trisopt Ophthalmic Suspension 5ml, potentially leading to enhanced hypotensive responses or central adverse effects.

There are no known food interactions with Trisopt Ophthalmic Suspension 5ml.

Trisopt Ophthalmic Suspension 5ml interacts with the following diseases:

• Cardiovascular Disease: Patients with cardiovascular disease might experience increased hypotension after using these drops.
• Raynaud's Phenomenon: Trisopt Ophthalmic Suspension 5ml should be used with caution in patients with Raynaud's phenomenon, as it may worsen peripheral vasospasm and reduce blood flow to the extremities.
• Orthostatic Hypotension: Trisopt Ophthalmic Suspension 5ml may increase the risk of symptomatic blood pressure drops on standing, particularly in patients predisposed to orthostatic hypotension.
• Thromboangiitis Obliterans: Caution is advised when using Trisopt Ophthalmic Suspension 5ml in patients with thromboangiitis obliterans, as it may aggravate peripheral circulatory impairment.
• Diabetes: Timolol can mask the symptoms of hypoglycaemia, such as rapid heartbeat, making it harder to recognise low blood sugar levels. Diabetic patients should monitor their blood glucose levels closely.
• Myasthenia Gravis: Timolol may exacerbate muscle weakness in patients with myasthenia gravis, leading to increased symptoms. Close monitoring and consultation with a healthcare provider are essential.

The daily dose of Trisopt Ophthalmic Suspension 5ml should be used as suggested by your doctor, considering factors like the severity of your condition and how you respond to this medication. Always adhere to the prescribed dosage, and never modify it without your doctor's advice.

If you accidentally use more Trisopt Ophthalmic Suspension 5ml than recommended, don't panic. Rinse your eyes with clean water at room temperature. If you notice persistent or worsening symptoms, inform your doctor.

If you miss a dose of Trisopt Ophthalmic Suspension 5ml, put it on as soon as you remember. If it is nearly time for the next dose, skip the missed dose and continue with your regular schedule. Never adjust your dosage without consulting your doctor.